PSI 938
Alternative Names: PSI-352938; PSI-938Latest Information Update: 20 Jan 2012
Price :
$50 *
At a glance
- Originator Pharmasset
- Class Antivirals; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences
- 01 Jan 2012 Pharmasset completes a phase I trial in Hepatitis C in USA and Puerto Rico (NCT01497327)
- 21 Dec 2011 Pharmasset initiates enrolment in a phase I trial to PSI-938 and PSI-7977 in Hepatitis C positive patients with hepatic impairment in the US and Puerto Rico (NCT01497327).